|
December 12, 2022
|
Neoleukin Therapeutics Presents Preclinical Data on NEO-TRA1 at American Society of Hematology (ASH) Annual Meeting
|
|
|
November 14, 2022
|
Neoleukin Therapeutics Announces Third Quarter 2022 Financial Results and Corporate Update
|
|
|
November 3, 2022
|
Neoleukin Therapeutics Announces Oral Presentation at 64th American Society of Hematology (ASH) Annual Meeting
|
|
|
August 9, 2022
|
Neoleukin Therapeutics Announces Second Quarter 2022 Financial Results & Provides Corporate Update
|
|
|
August 3, 2022
|
Neoleukin Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference
|
|
|
July 27, 2022
|
Neoleukin Therapeutics to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 9, 2022
|
|
|
May 16, 2022
|
Neoleukin Therapeutics Announces First Patient Treated in Combination Arm of Phase 1 Trial Evaluating NL-201 in Combination with KEYTRUDA® (pembrolizumab)
|
|
|
May 9, 2022
|
Neoleukin Therapeutics Announces First Quarter 2022 Financial Results and Corporate Update
|
|
|
May 5, 2022
|
Neoleukin Therapeutics to Present at Upcoming Investor Conferences
|
|
|
April 13, 2022
|
Neoleukin Therapeutics Announces Preclinical Data for NL-201 at American Association for Cancer Research (AACR) Annual Meeting
|
|
